Glycopyrrolate Injection shortage
To Be Discontinued 4 presentations · 1 manufacturers · first FDA posting 2026-07-30 · last update 2026-07-30
Manufacturers: Fresenius Kabi USA, LLC
Stated reasons (per FDA): Not stated
Presentations
| Presentation | Manufacturer | Status | Reason | Notes (FDA) | Dates |
|---|---|---|---|---|---|
| Glycopyrrolate, Injection, .2 mg/1 mL (NDC 63323-578-01) | Fresenius Kabi USA, LLC | To Be Discontinued | — | Discontinuation of the manufacture of the drug | Posted 07/30/2026 Updated 07/30/2026 Discontinued 07/30/2026 |
| Glycopyrrolate, Injection, 0.4 mg per 2 mL (NDC 63323-578-02) | Fresenius Kabi USA, LLC | To Be Discontinued | — | Discontinuation of the manufacture of the drug | Posted 07/30/2026 Updated 07/30/2026 Discontinued 07/30/2026 |
| Glycopyrrolate, Injection, 1 mg per 5 mL (NDC 63323-578-05) | Fresenius Kabi USA, LLC | To Be Discontinued | — | Discontinuation of the manufacture of the drug | Posted 07/30/2026 Updated 07/30/2026 Discontinued 07/30/2026 |
| Glycopyrrolate, Injection, 0.2 mg per 1 mL (NDC 65219-801-01) | Fresenius Kabi USA, LLC | To Be Discontinued | — | Discontinuation of the manufacture of the drug | Posted 07/30/2026 Updated 07/30/2026 Discontinued 07/30/2026 |
Get the weekly shortage roundup: a free email of FDA shortage changes (open form)